An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

January 1, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

ACR246 for injection

80 mg/vial

Trial Locations (3)

RECRUITING

Beijing Tumor Hospital, Beijing

RECRUITING

Shandong First Medical University affiliated Cancer Hospital of Shandong, Shandong

RECRUITING

Zhejiang Cancer Hospital, Zhejiang